Brokerages expect that Heska Corporation (NASDAQ:HSKA) will announce earnings of $0.42 per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Heska Corporation’s earnings. The highest EPS estimate is $0.46 and the lowest is $0.38. Heska Corporation reported earnings per share of $0.45 in the same quarter last year, which suggests a negative year-over-year growth rate of 6.7%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that Heska Corporation will report full-year earnings of $2.01 per share for the current year, with EPS estimates ranging from $2.00 to $2.03. For the next year, analysts anticipate that the firm will report earnings of $2.10 per share, with EPS estimates ranging from $2.00 to $2.25. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that follow Heska Corporation.

Heska Corporation (NASDAQ:HSKA) last posted its earnings results on Thursday, August 3rd. The medical research company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Heska Corporation had a net margin of 10.70% and a return on equity of 15.87%. The business had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $33.35 million. During the same period in the previous year, the company posted $0.35 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year.

HSKA has been the subject of several research reports. Zacks Investment Research raised Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 target price for the company in a research report on Friday, August 4th. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 3rd. Benchmark Co. raised their target price on Heska Corporation from $106.00 to $120.00 and gave the company a “buy” rating in a research note on Thursday, August 3rd. Aegis started coverage on Heska Corporation in a research note on Thursday, June 1st. They issued a “buy” rating and a $114.50 target price for the company. Finally, B. Riley restated a “neutral” rating and issued a $96.50 target price on shares of Heska Corporation in a research note on Thursday, August 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $105.20.

In other Heska Corporation news, EVP Nancy Wisnewski sold 250 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $100.17, for a total transaction of $25,042.50. Following the transaction, the executive vice president now owns 38,901 shares of the company’s stock, valued at approximately $3,896,713.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Michael J. Mcginley sold 11,189 shares of the business’s stock in a transaction that occurred on Wednesday, May 31st. The stock was sold at an average price of $98.53, for a total value of $1,102,452.17. Following the transaction, the insider now directly owns 111,877 shares in the company, valued at approximately $11,023,240.81. The disclosure for this sale can be found here. Insiders have sold a total of 30,265 shares of company stock worth $2,983,439 in the last quarter. 14.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. bought a new position in Heska Corporation during the first quarter valued at $101,000. BNP Paribas Arbitrage SA raised its position in Heska Corporation by 1,306.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,167 shares of the medical research company’s stock worth $123,000 after buying an additional 1,084 shares during the last quarter. State of Alaska Department of Revenue acquired a new position in Heska Corporation during the second quarter worth $127,000. LS Investment Advisors LLC raised its position in Heska Corporation by 411.2% in the second quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock worth $130,000 after buying an additional 1,028 shares during the last quarter. Finally, Mason Street Advisors LLC acquired a new position in Heska Corporation during the first quarter worth $144,000. 81.48% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “$0.42 EPS Expected for Heska Corporation (NASDAQ:HSKA) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/11/0-42-eps-expected-for-heska-corporation-nasdaqhska-this-quarter.html.

Heska Corporation (NASDAQ HSKA) traded down 0.26% during mid-day trading on Friday, reaching $95.64. 31,883 shares of the company traded hands. Heska Corporation has a 52-week low of $46.51 and a 52-week high of $115.00. The company has a market capitalization of $691.09 million, a P/E ratio of 48.75 and a beta of 0.82. The stock has a 50 day moving average price of $101.48 and a 200-day moving average price of $95.74.

Heska Corporation Company Profile

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Get a free copy of the Zacks research report on Heska Corporation (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska Corporation (NASDAQ:HSKA)

Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.